|
|
Exchange: |
|
Security
Type: |
|
Shares
Out: |
8,100,000 |
Market
Cap: |
492.48(K) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.0551 - $0.3974 |
|
Level
I Sector: |
|
Level
II Sector: |
|
Level
III Sector: |
|
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aridis Pharmaceuticals is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using human monoclonal antibodies (mAbs) to treat infections. Co.'s product candidates include: AR-301, which is a human immunoglobulin 1 (IgG1) mAb targeting the gram-positive bacteria S. aureus alphatoxin; AR-320, which is a human, IgG1 monoclonal antibody targeting S. aureus alpha toxin; AR-501 (Panaecin), which is a spectrum small molecule anti-infective Co. is developing in addition to its targeted mAb product candidates; and AR-101, which is a human immunoglobulin M mAb targeting the gram-negative bacteria P. aeruginosa serotype O11.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Patzer Eric |
Executive Chairman |
|
2023-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,000 |
714,132 |
|
- |
|
Kurland Fred |
CFO |
|
2023-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
4,000 |
|
- |
|
Windham-Bannister Susan Richards |
Director |
|
2023-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
Truong Vu |
CEO and Director |
|
2023-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
752,353 |
|
- |
|
Hamilton John F |
Director |
|
2023-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
Jafri Hasan |
Chief Medical Officer |
|
2023-06-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
15,100 |
|
- |
|
Cystic Fibrosis Foundation |
10% Owner |
|
2022-12-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,168,732 |
|
-76% |
|
Jafri Hasan |
Chief Medical Officer |
|
2021-09-07 |
4 |
B |
$3.97 |
$8,660 |
D/D |
2,091 |
5,100 |
2.74 |
-64% |
|
Jafri Hasan |
Chief Medical Officer |
|
2021-09-03 |
4 |
B |
$4.15 |
$12,487 |
D/D |
3,009 |
3,009 |
2.74 |
-65% |
|
Truong Vu |
CEO |
|
2021-07-27 |
4 |
B |
$5.11 |
$25,550 |
D/D |
5,000 |
737,353 |
2.81 |
-58% |
|
Patzer Eric |
Director |
|
2021-07-27 |
4 |
B |
$4.84 |
$25,047 |
D/D |
5,175 |
702,132 |
2.39 |
-58% |
|
Hamilton John F |
Director |
|
2021-07-27 |
4 |
B |
$4.87 |
$9,740 |
D/D |
2,000 |
2,000 |
2.39 |
-58% |
|
Patzer Eric |
Chairman |
|
2020-12-22 |
4 |
GD |
$0.00 |
$0 |
D/D |
16,000 |
696,957 |
|
- |
|
13 Records found
|
1
|
Page 1 of 1 |
|
|